Health Trials

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

ConditionsArthritisPolymyalgia RheumaticaImmune Checkpoint Inhibitors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center

About this trial

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Eligibility criteria

Qualifiers

Patients aged 18 years and above

English (conversational level) speaking, with the ability to give informed consent

Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy

Disqualifiers

Acutely life-threatening or worsening cancer

Hearing impairment functionally limiting participation in verbal interview

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

M.D. Anderson Cancer Center

Lead sponsor

Source ClinicalTrials.gov